ATE365173T1 - Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine - Google Patents

Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine

Info

Publication number
ATE365173T1
ATE365173T1 AT00932412T AT00932412T ATE365173T1 AT E365173 T1 ATE365173 T1 AT E365173T1 AT 00932412 T AT00932412 T AT 00932412T AT 00932412 T AT00932412 T AT 00932412T AT E365173 T1 ATE365173 T1 AT E365173T1
Authority
AT
Austria
Prior art keywords
sub
line
formulae
amino acid
modified form
Prior art date
Application number
AT00932412T
Other languages
English (en)
Inventor
Richard Gordon
Deborah Moorad
Bhupendra Doctor
Gregory Garcia
Original Assignee
Us Army Med Res Mat Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Med Res Mat Command filed Critical Us Army Med Res Mat Command
Application granted granted Critical
Publication of ATE365173T1 publication Critical patent/ATE365173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00932412T 1999-05-17 2000-05-15 Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine ATE365173T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13444699P 1999-05-17 1999-05-17

Publications (1)

Publication Number Publication Date
ATE365173T1 true ATE365173T1 (de) 2007-07-15

Family

ID=22463433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932412T ATE365173T1 (de) 1999-05-17 2000-05-15 Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine

Country Status (9)

Country Link
US (3) US6573244B1 (de)
EP (1) EP1179010B1 (de)
JP (1) JP2003501012A (de)
AT (1) ATE365173T1 (de)
AU (1) AU772985B2 (de)
CA (1) CA2372304A1 (de)
DE (1) DE60035270D1 (de)
IL (1) IL146459A0 (de)
WO (1) WO2000069891A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6713444B1 (en) * 1999-05-14 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE10038511A1 (de) * 2000-08-08 2002-02-21 Bhs Corr Masch & Anlagenbau Längs-Bearbeitungs-Maschine für Wellpappe-Bahnen
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7350590B2 (en) * 2002-11-05 2008-04-01 Weatherford/Lamb, Inc. Instrumentation for a downhole deployment valve
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8658372B2 (en) * 2005-06-10 2014-02-25 The United States Of America, As Represented By The Secretary Of The Navy Affinity-based detection of biological targets
US20070154448A1 (en) 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059693A (en) * 1976-06-11 1977-11-22 University Patents, Inc. Analgesic action of substance P
US5137873A (en) * 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
EP0593615B1 (de) * 1991-07-10 1996-01-31 MERCK SHARP & DOHME LTD. Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
WO1993001159A1 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
CA2260269A1 (en) * 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins

Also Published As

Publication number Publication date
WO2000069891A2 (en) 2000-11-23
AU772985B2 (en) 2004-05-13
CA2372304A1 (en) 2000-11-23
US20060247176A1 (en) 2006-11-02
EP1179010B1 (de) 2007-06-20
US7375079B2 (en) 2008-05-20
US20050113304A1 (en) 2005-05-26
US6573244B1 (en) 2003-06-03
DE60035270D1 (de) 2007-08-02
WO2000069891A9 (en) 2002-07-04
AU5013600A (en) 2000-12-05
JP2003501012A (ja) 2003-01-14
EP1179010A2 (de) 2002-02-13
IL146459A0 (en) 2002-07-25
WO2000069891A3 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
ATE365173T1 (de) Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
NZ520659A (en) Xylanase variants having altered sensitivity to xylanase inhibitors caused by mutations in the lid region
DE69434817D1 (de) Protease varianten
DE69033699T2 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
DE69226182T2 (de) Stabilisierte enzyme und waschmittelzusammensetzungen
DE69633228D1 (de) Botulinumtoxinderivate die periferishe sensorische afferende funktionen ändern können
DK1653989T3 (da) Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
ATE245185T1 (de) Proteasen enthaltende bleichmittelzusammensetzungen
ATE228856T1 (de) Mittel für die steuerung von der zellaktivität
EA200200017A1 (ru) Терапевтическое средство с ботулиническим нейротоксином
DE69717474D1 (de) Durch cyclische aminosäuren oder cyclische hydroxysäuren substituierte benzamidinderivate und deren verwendung als antikoagulantien
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
DE69101557D1 (de) Enzymatische waschmittelzusammensetzung und verfahren zum stabilisieren der enzyme.
BRPI0407294A (pt) Protease da famìlia de peptidases s2a e/ou famìlia de peptidases s1e, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para produzir um polipeptìdeo, planta transgênica, ou parte de planta, animal transgênico não-humano ou produtos ou elementos dos mesmos, uso de pelo menos um polipeptìdeo, aditivo de ração animal, composição de ração animal, e, composição detergente
BR9909130A (pt) Variantes de protease de serina tendo substituições de amino-ácido
NO20005261L (no) Nye heterocyklisk substituerte amider med cystein-protease- inhiberende virkning
DE69728869D1 (de) Von aminosauren und hydroxysauren substituierte benzamidinderivate und deren verwendung als antikoagulantien
ATE382604T1 (de) Aminosäure-derivate als hiv aspartyl-protease- inhibitoren
ATE153670T1 (de) Peptidboronsäurederivate mit protease inhibierenden aktivität
BR9911891A (pt) Proteases fundidas com variantes de inibidor de subtilisina de streptomyces
PT830130E (pt) Enzima de conversao de tnf-alfa
Burchacka et al. Phosphonic analogues of glutamic acid as irreversible inhibitors of Staphylococcus aureus endoproteinase GluC: an efficient synthesis and inhibition of the human IgG degradation
ATE92935T1 (de) Serinproteaseinhibitoren und isolierungsverfahren dazu.
WO2000069895A3 (en) Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties